
|Videos|October 9, 2016
Significant Disparities in Access to Novel Agents For Patients With Melanoma
Author(s)Lidija Kandolf Sekulovic, MD, PhD
Lidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 LAGOON Trial Fails to Confirm Survival Benefit of Lurbinectedin in Relapsed SCLC
2
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer
3
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
4
The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports
5







































